These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 31796521)

  • 1. Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer.
    Hong DS; Concin N; Vergote I; de Bono JS; Slomovitz BM; Drew Y; Arkenau HT; Machiels JP; Spicer JF; Jones R; Forster MD; Cornez N; Gennigens C; Johnson ML; Thistlethwaite FC; Rangwala RA; Ghatta S; Windfeld K; Harris JR; Lassen UN; Coleman RL
    Clin Cancer Res; 2020 Mar; 26(6):1220-1228. PubMed ID: 31796521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.
    Coleman RL; Lorusso D; Gennigens C; González-Martín A; Randall L; Cibula D; Lund B; Woelber L; Pignata S; Forget F; Redondo A; Vindeløv SD; Chen M; Harris JR; Smith M; Nicacio LV; Teng MSL; Laenen A; Rangwala R; Manso L; Mirza M; Monk BJ; Vergote I;
    Lancet Oncol; 2021 May; 22(5):609-619. PubMed ID: 33845034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial.
    de Bono JS; Concin N; Hong DS; Thistlethwaite FC; Machiels JP; Arkenau HT; Plummer R; Jones RH; Nielsen D; Windfeld K; Ghatta S; Slomovitz BM; Spicer JF; Yachnin J; Ang JE; Mau-Sørensen PM; Forster MD; Collins D; Dean E; Rangwala RA; Lassen U
    Lancet Oncol; 2019 Mar; 20(3):383-393. PubMed ID: 30745090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer.
    Vergote I; González-Martín A; Fujiwara K; Kalbacher E; Bagaméri A; Ghamande S; Lee JY; Banerjee S; Maluf FC; Lorusso D; Yonemori K; Van Nieuwenhuysen E; Manso L; Woelber L; Westermann A; Covens A; Hasegawa K; Kim BG; Raimondo M; Bjurberg M; Cruz FM; Angelergues A; Cibula D; Barraclough L; Oaknin A; Gennigens C; Nicacio L; Teng MSL; Whalley E; Soumaoro I; Slomovitz BM;
    N Engl J Med; 2024 Jul; 391(1):44-55. PubMed ID: 38959480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of the novel tissue factor antibody-drug conjugate: Tisotumab vedotin.
    Luu K; Chu A; Chang B
    J Oncol Pharm Pract; 2023 Mar; 29(2):441-449. PubMed ID: 36415085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tisotumab vedotin for the treatment of cervical carcinoma.
    Song X; Li R; Wang H; Song P; Guo W; Chen ZS
    Drugs Today (Barc); 2022 May; 58(5):213-222. PubMed ID: 35535813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tisotumab Vedotin: First Approval.
    Markham A
    Drugs; 2021 Dec; 81(18):2141-2147. PubMed ID: 34748188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitigation and management strategies for ocular events associated with tisotumab vedotin.
    Kim SK; Ursell P; Coleman RL; Monk BJ; Vergote I
    Gynecol Oncol; 2022 May; 165(2):385-392. PubMed ID: 35277279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tisotumab vedotin in Japanese patients with recurrent/metastatic cervical cancer: Results from the innovaTV 206 study.
    Yonemori K; Kuboki Y; Hasegawa K; Iwata T; Kato H; Takehara K; Hirashima Y; Kato H; Passey C; Buchbjerg JK; Harris JR; Andreassen CM; Nicacio L; Soumaoro I; Fujiwara K
    Cancer Sci; 2022 Aug; 113(8):2788-2797. PubMed ID: 35633184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Review of Tisotumab Vedotin-tftv in Recurrent or Metastatic Cervical Cancer.
    Heitz N; Greer SC; Halford Z
    Ann Pharmacother; 2023 May; 57(5):585-596. PubMed ID: 35962528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of tisotumab vedotin as a second- or third-line therapy for cervical cancer.
    Huo G; Liu W; Chen P
    J Gynecol Oncol; 2024 Sep; 35(5):e58. PubMed ID: 38330381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study.
    Vergote I; Van Nieuwenhuysen E; O'Cearbhaill RE; Westermann A; Lorusso D; Ghamande S; Collins DC; Banerjee S; Mathews CA; Gennigens C; Cibula D; Tewari KS; Madsen K; Köse F; Jackson AL; Boere IA; Scambia G; Randall LM; Sadozye A; Baurain JF; Gort E; Zikán M; Denys HG; Ottevanger N; Forget F; Mondrup Andreassen C; Eaton L; Chisamore MJ; Viana Nicacio L; Soumaoro I; Monk BJ
    J Clin Oncol; 2023 Dec; 41(36):5536-5549. PubMed ID: 37651655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer.
    O'Malley DM; Oaknin A; Monk BJ; Selle F; Rojas C; Gladieff L; Berton D; Leary A; Moore KN; Estevez-Diz MDP; Hardy-Bessard AC; Alexandre J; Opperman CP; de Azevedo CRAS; Randall LM; Feliu WO; Ancukiewicz M; Ray-Coquard I
    Gynecol Oncol; 2021 Nov; 163(2):274-280. PubMed ID: 34452745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tisotumab vedotin in recurrent or metastatic cervical cancer.
    Bogani G; Coleman RL; Vergote I; Raspagliesi F; Lorusso D; Monk BJ
    Curr Probl Cancer; 2023 Jun; 47(3):100952. PubMed ID: 36842202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study.
    Chung HC; Ros W; Delord JP; Perets R; Italiano A; Shapira-Frommer R; Manzuk L; Piha-Paul SA; Xu L; Zeigenfuss S; Pruitt SK; Leary A
    J Clin Oncol; 2019 Jun; 37(17):1470-1478. PubMed ID: 30943124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 2 study of nanoparticle albumin-bound paclitaxel plus nedaplatin for patients with advanced, recurrent, or metastatic cervical carcinoma.
    Li Y; Zeng J; Huang M; An J; Bai P; Wu L; Zhang R
    Cancer; 2017 Feb; 123(3):420-425. PubMed ID: 27696395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Drug Treats Cervical Cancer.
    Aschenbrenner DS
    Am J Nurs; 2022 Jan; 122(1):21. PubMed ID: 34941590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial.
    Naumann RW; Hollebecque A; Meyer T; Devlin MJ; Oaknin A; Kerger J; López-Picazo JM; Machiels JP; Delord JP; Evans TRJ; Boni V; Calvo E; Topalian SL; Chen T; Soumaoro I; Li B; Gu J; Zwirtes R; Moore KN
    J Clin Oncol; 2019 Nov; 37(31):2825-2834. PubMed ID: 31487218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Efficacy and Safety of Apatinib for the Treatment of Patients with Metastatic, Recurrent Cervical Cancer after Failure of Radiotherapy and First-Line Chemotherapy: A Prospective Study.
    Xia X; Jiang W; Qi W; Hong B; Zhao W
    Oncol Res Treat; 2020; 43(12):649-655. PubMed ID: 33045704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma.
    Ott PA; Pavlick AC; Johnson DB; Hart LL; Infante JR; Luke JJ; Lutzky J; Rothschild NE; Spitler LE; Cowey CL; Alizadeh AR; Salama AK; He Y; Hawthorne TR; Bagley RG; Zhang J; Turner CD; Hamid O
    Cancer; 2019 Apr; 125(7):1113-1123. PubMed ID: 30690710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.